Eric Cannon, PharmD, FAMCP

Eric Cannon, PharmD, FAMCP, discusses how the PDE4B pathway promotes inflammation and fibrosis in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) by regulating cAMP levels and fibroblast activity. Nerandomilast has shown promising anti-inflammatory and antifibrotic effects in preclinical models, with early clinical trials suggesting good tolerability and potential lung function stabilization. However, larger phase 3 trials with longer follow-up are needed to confirm efficacy, safety and impact on disease progression.